Study of zanidatamab for HER2-positive solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Mouth & dental, Skin, Women’s health & pregnancy clinical trials.
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your cancer has spread or cannot be removed with surgery, and you have already tried at least one prior treatment.
- Your tumor is HER2-positive (IHC 3+) as confirmed by the study's central lab.
- You have a tumor sample that can be tested for HER2.
- You have at least one measurable tumor on scans.
- You are generally well enough to be active (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called zanidatamab in people with certain cancers (endometrial, colorectal, head & neck, non-small cell lung, or sarcoma) that have a specific change in the HER2 gene. It's for those whose cancer has spread or can't be removed and who have tried at least one prior treatment.
This study observes people with advanced HER2-positive stomach or esophageal cancer who are starting a treatment that includes zanidatamab. It collects information about their experiences and quality of life during treatment.
This trial tests a new targeted drug called zanidatamab given with standard chemotherapy before surgery for HER2-positive stomach or gastroesophageal junction cancer. It aims to shrink the tumor enough to allow successful removal, either for cancers that were initially too advanced for surgery or for those with high-risk features.
This trial is testing a combination of two targeted drugs (zanidatamab and tucatinib) plus chemotherapy for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. It's for those who have already had at least one other anti-HER2 treatment but no more than three.
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
This trial tests zanidatamab, a type of targeted antibody treatment, in people with early-stage HER2-positive breast cancer to see how well it works and how safe it is. Because it’s a single-arm pilot study, everyone in the study gets the drug, and you’ll likely be asked to undergo standard surgery if appropriate.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.